XFOR

X 4 Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↑ 6/10
  • Value↓ 0/10
X 4 Pharmaceuticals sales and earnings growth
XFOR Growth
Good
  • Revenue Y/Y↑ 1273.21%
  • EPS Y/Y↑ 66.55%
  • FCF Y/Y↑ 35.89%
X 4 Pharmaceuticals gross and profit margin trends
XFOR Profitability
Neutral
  • Gross margin ↑ 83.60%
  • EPS margin↓ -225.60%
  • ROIC 5Y↓ -134.38%
X 4 Pharmaceuticals net debt vs free cash flow
XFOR Risk
Great
  • Debt / Equity↓ 0.4
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -7.9

X 4 Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗